Difference between revisions of "User:FletaAlderman"
m |
m |
||
| Line 1: | Line 1: | ||
| − | + | Nonetheless, all of this potential does not come cheaply. Hospira's 2012 Annual Report estimates a cost of $100 $200M per approved biosimilar drug over a 7 8 year period of research and development. | |
Revision as of 07:03, 2 May 2019
Nonetheless, all of this potential does not come cheaply. Hospira's 2012 Annual Report estimates a cost of $100 $200M per approved biosimilar drug over a 7 8 year period of research and development.
